NO20085243L - Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting - Google Patents

Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting

Info

Publication number
NO20085243L
NO20085243L NO20085243A NO20085243A NO20085243L NO 20085243 L NO20085243 L NO 20085243L NO 20085243 A NO20085243 A NO 20085243A NO 20085243 A NO20085243 A NO 20085243A NO 20085243 L NO20085243 L NO 20085243L
Authority
NO
Norway
Prior art keywords
treatment
pharmaceutical composition
protein
inhibition
viral infections
Prior art date
Application number
NO20085243A
Other languages
English (en)
Norwegian (no)
Inventor
Ulrich Schubert
Original Assignee
Virologik Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virologik Gmbh filed Critical Virologik Gmbh
Publication of NO20085243L publication Critical patent/NO20085243L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20085243A 2006-06-01 2008-12-15 Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting NO20085243L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006026464A DE102006026464A1 (de) 2006-06-01 2006-06-01 Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
PCT/EP2007/055425 WO2007138116A2 (fr) 2006-06-01 2007-06-01 Composition pharmaceutique pour traiter des infections virales et/ou des maladies tumorales par inhibition du repliement et de la décomposition des protéines

Publications (1)

Publication Number Publication Date
NO20085243L true NO20085243L (no) 2009-02-27

Family

ID=38626699

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085243A NO20085243L (no) 2006-06-01 2008-12-15 Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting

Country Status (15)

Country Link
US (1) US20090156473A1 (fr)
EP (1) EP2029125A2 (fr)
JP (1) JP2009538881A (fr)
KR (1) KR20090048403A (fr)
CN (1) CN101453998A (fr)
AU (1) AU2007267082A1 (fr)
BR (1) BRPI0712459A2 (fr)
CA (1) CA2654276A1 (fr)
DE (1) DE102006026464A1 (fr)
IL (1) IL195611A0 (fr)
MX (1) MX2008015259A (fr)
NO (1) NO20085243L (fr)
RU (1) RU2008152796A (fr)
WO (1) WO2007138116A2 (fr)
ZA (1) ZA200810531B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
CN103554222A (zh) 2004-04-15 2014-02-05 欧尼斯治疗公司 用于抑制蛋白酶体酶的化合物
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
SI2030981T1 (sl) * 2004-05-10 2014-11-28 Onyx Therapeutics, Inc. Spojine za inhibiranje proteasomskega encima
JP5676071B2 (ja) 2004-12-03 2015-02-25 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 腫瘍性疾患を治療するための組成物及び方法
AU2006311584B2 (en) 2005-11-09 2012-03-08 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
AU2007261345B2 (en) 2006-06-19 2012-02-23 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
US7824698B2 (en) 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
US20080280968A1 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
DE102007031397A1 (de) 2007-07-05 2009-01-08 D2O Bioscience Group Ltd. Verwendung von Deuteriumoxid zur Behandlung von Virus-basierten Erkrankungen der Haut
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
EP2237684A2 (fr) * 2008-01-08 2010-10-13 Akthelia Pharmaceuticals Agonistes pour des systèmes peptidiques antimicrobiens
KR20110011645A (ko) 2008-05-12 2011-02-08 니리어스 파마슈티컬즈, 인코퍼레이션 프로테아좀 저해제로서의 살리노스포라마이드 유도체
CA2741312C (fr) * 2008-10-21 2020-10-27 Onyx Therapeutics, Inc. Therapie de combinaison avec des peptides epoxycetones
DE102009003992A1 (de) * 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Respirationstraktes
DE102009003942A1 (de) * 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
JP2013500265A (ja) * 2009-07-23 2013-01-07 ザ トラスティーズ オブ プリンストン ユニバーシティ 抗ウイルス剤として用いられるｍＴＯＲキナーゼ阻害剤
WO2011009961A1 (fr) * 2009-07-24 2011-01-27 Virologik Gmbh Association d'inhibiteurs du protéasome et de médicaments anti-hépatite dans le traitement de l'hépatite
CN102051407B (zh) * 2009-11-09 2012-12-12 中国医学科学院医药生物技术研究所 Hiv-1前体蛋白早成熟化诱导剂的筛选方法
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
WO2011096756A2 (fr) * 2010-02-04 2011-08-11 이화여자대학교 산학협력단 Composition pharmaceutique destinée à inhiber la prolifération anormale de cellules
SG183843A1 (en) 2010-03-01 2012-10-30 Onyx Therapeutics Inc Compounds for immunoproteasome inhibition
MX2012011604A (es) 2010-04-07 2013-02-27 Onyx Therapeutics Inc Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino.
GB2506085A (en) 2011-10-21 2014-03-19 Abbvie Inc Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
JP6028968B2 (ja) * 2012-02-24 2016-11-24 学校法人順天堂 抗インフルエンザウイルス剤
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
CN105477007B (zh) * 2014-09-15 2020-02-18 中国医学科学院药物研究所 大环内酯类药物在抗丝状病毒感染中的应用
CN105675572B (zh) * 2016-03-15 2018-09-14 四川大学华西医院 一种肺癌筛查试剂盒
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
US11266675B2 (en) * 2018-04-30 2022-03-08 City University Of Hong Kong Methods of treatment of viral infection and uses of anti-HSC70 inhibitors
CN108635584B (zh) * 2018-05-22 2021-12-21 广州威溶特医药科技有限公司 蛋白酶体抑制剂和甲病毒在制备抗肿瘤药物中的应用
CN110133286A (zh) * 2019-05-20 2019-08-16 吉林大学 Hsp60基因作为靶点在脑膜炎治疗中的医用用途
CN111514299A (zh) * 2020-04-29 2020-08-11 广州中医药大学科技产业园有限公司 一种用于防治肺炎的组合物及其在制备用于防治肺炎的药物中的应用
WO2021231397A1 (fr) * 2020-05-13 2021-11-18 The Regents Of The University Of California Thiosaccharides destinés à être utilisés dans le traitement d'une infection à coronavirus
WO2021263139A1 (fr) * 2020-06-26 2021-12-30 Duke University Procédés de traitement d'une infection à coronavirus au moyen d'inhibiteurs de hsp90

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2219867A1 (fr) * 1997-10-31 1999-04-30 Jiangping Wu Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique
US20020049157A1 (en) * 1999-08-25 2002-04-25 Jiangping Wu Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
CA2425632A1 (fr) * 2000-10-12 2002-04-18 Viromics Gmbh Moyens pour le traitement d'infections a des virus
WO2002080907A1 (fr) * 2001-04-03 2002-10-17 Millennium Pharmaceuticals, Inc. Combinaison d'analogue de lactacystine et de medicament immunosuppresseur permettant la prolongation de la survie d'une allogreffe
DE10361944A1 (de) * 2003-12-31 2005-07-28 Viromics Gmbh Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung
WO2005115431A2 (fr) * 2004-05-24 2005-12-08 Adonia Papathanassiu Procedes pour inhiber des proteasomes et la proteine de choc thermique 90
MX2007013499A (es) * 2005-04-29 2008-01-24 Kosan Biosciences Inc Metodo para tratar mieloma multiple utilizando 17-aag o 17-ag o un profarmaco de ya sea 17-aag o 17-ag en combinacion con un inhibidor de proteasoma.
WO2007059116A2 (fr) * 2005-11-14 2007-05-24 Abraxis Bioscience, Inc. Derives de geldanamycine et compositions pharmaceutiques associees

Also Published As

Publication number Publication date
US20090156473A1 (en) 2009-06-18
WO2007138116A2 (fr) 2007-12-06
MX2008015259A (es) 2009-03-26
KR20090048403A (ko) 2009-05-13
DE102006026464A1 (de) 2007-12-06
RU2008152796A (ru) 2010-07-20
CN101453998A (zh) 2009-06-10
BRPI0712459A2 (pt) 2012-07-31
WO2007138116A3 (fr) 2008-05-08
EP2029125A2 (fr) 2009-03-04
AU2007267082A1 (en) 2007-12-06
JP2009538881A (ja) 2009-11-12
ZA200810531B (en) 2009-11-25
CA2654276A1 (fr) 2007-12-06
IL195611A0 (en) 2009-09-01

Similar Documents

Publication Publication Date Title
NO20085243L (no) Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
CY1112383T1 (el) Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
EA200870019A1 (ru) Лактамовые соединения и способы их применения
ECSP099685A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
EA200901308A1 (ru) Ингибиторы белка, активирующего 5-липоксигеназу (flap)
BR112012024661A2 (pt) composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
BRPI0606524A2 (pt) derivados de indol para o tratamento de infecções virais
BRPI0612309B8 (pt) compostos e composições farmacêuticas antivirais
ZA200805304B (en) Anti-viral compounds
EA200900298A1 (ru) Ингибиторы вируса гепатита с
WO2008133753A3 (fr) Composés antiviraux
EA200870164A1 (ru) Лечение вирусного гепатита
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
EA200800178A1 (ru) Ингибиторы вируса гепатита с (hcv)
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
EA200901241A1 (ru) Соединения для лечения гепатита с
EA201170441A1 (ru) Терапевтические противовирусные пептиды
EA200970483A1 (ru) Применение пролекарств габапентина и прегабалина для лечения шума в ушах
EA201000277A1 (ru) Соединения для лечения гепатита с
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
EA201171273A1 (ru) Средство для профилактики и лечения высокопатогенных инфекционных заболеваний

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application